Skip to main content
SpringerLink
Log in

Synthetic Antibodies in Infectious Disease

  • Chapter
  • First Online:
Recombinant Antibodies for Infectious Diseases

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1053))

Abstract

Rapid spread of microbial resistance and recent outbreaks of viral disease have led to renewed interest in antibody-based therapies for infectious diseases. Synthetic antibody libraries displayed on phage offer unique advantages over traditional immunization-based antibody generation, including full control over library design and selection conditions. The technology has matured beyond natural antibodies and is capable of providing novel insights into infectious disease and can generate novel antibodies that cannot be produced by the natural immune system. This chapter gives an overview of recombinant antibody library technology with an emphasis on our work using a highly successful synthetic single framework Fab library. We demonstrate its utility in targeting viruses and bacterial toxins in five case studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 189.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Adams JJ, Sidhu SS (2014) Synthetic antibody technologies. Curr Opin Struct Biol 24:1–9

    Article  CAS  PubMed  Google Scholar 

  2. Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619–1633

    CAS  PubMed  Google Scholar 

  3. Avnir Y, Tallarico AS, Zhu Q, Bennett AS, Connelly G, Sheehan J, Sui J, Fahmy A, Huang CY, Cadwell G, Bankston LA, McGuire AT, Stamatatos L, Wagner G, Liddington RC, Marasco WA (2014) Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog 10(5):e1004103

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Badran AH, Liu DR (2015) In vivo continuous directed evolution. Curr Opin Chem Biol 24:1–10

    Article  CAS  PubMed  Google Scholar 

  5. Barbas CF 3rd, Bain JD, Hoekstra DM, Lerner RA (1992) Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc Natl Acad Sci U S A 89(10):4457–4461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Barbas CF 3rd, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL, Burton DR (1994) In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A 91(9):3809–3813

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Barthelemy PA, Raab H, Appleton BA, Bond CJ, Wu P, Wiesmann C, Sidhu SS (2008) Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem 283(6):3639–3654

    Article  CAS  PubMed  Google Scholar 

  8. Bebbington C, Yarranton G (2008) Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 19(6):613–619

    Article  CAS  PubMed  Google Scholar 

  9. Beerli RR, Rader C (2010) Mining human antibody repertoires. MAbs 2(4):365–378

    Article  PubMed  Google Scholar 

  10. Birtalan S, Fisher RD, Sidhu SS (2010) The functional capacity of the natural amino acids for molecular recognition. Mol BioSyst 6(7):1186–1194

    Article  CAS  PubMed  Google Scholar 

  11. Both GW, Sleigh MJ, Cox NJ, Kendal AP (1983) Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 48(1):52–60

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Bradbury AR, Sidhu S, Dubel S, McCafferty J (2011) Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 29(3):245–254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM (2012) Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol 86(1):364–372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bruggemann M, Caskey HM, Teale C, Waldmann H, Williams GT, Surani MA, Neuberger MS (1989) A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci U S A 86(17):6709–6713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR (2011) Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477(7364):340–343

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6(5):343–357

    Article  CAS  PubMed  Google Scholar 

  17. Casadevall A (1996) Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis 2(3):200–208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308(5728):1643–1645

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chen G, Gorelik L, Simon KJ, Pavlenco A, Cheung A, Brickelmaier M, Chen LL, Jin P, Weinreb PH, Sidhu SS (2015) Synthetic antibodies and peptides recognizing progressive multifocal leukoencephalopathy-specific point mutations in polyomavirus JC capsid viral protein 1. MAbs 7(4):681–692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chen G, Koellhoffer JF, Zak SE, Frei JC, Liu N, Long H, Ye W, Nagar K, Pan G, Chandran K, Dye JM, Sidhu SS, Lai JR (2014) Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS Chem Biol 9(10):2263–2273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Chen W, Zhu Z, Feng Y, Dimitrov DS (2008) Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A 105(44):17121–17126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Cobaugh CW, Almagro JC, Pogson M, Iverson B, Georgiou G (2008) Synthetic antibody libraries focused towards peptide ligands. J Mol Biol 378(3):622–633

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–742

    Article  CAS  PubMed  Google Scholar 

  24. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ (2016) Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351(6279):1339–1342

    Article  CAS  PubMed  Google Scholar 

  25. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333(6044):850–856

    Article  CAS  PubMed  Google Scholar 

  26. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J (2011) Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477(7364):344–348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Olafsdottir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH (2016) Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 16(2):239–251

    Article  CAS  PubMed  Google Scholar 

  28. Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, Halfmann P, Muhammad MA, Fusco ML, Zak SE, Kang E, Kawaoka Y, Chandran K, Dye JM, Saphire EO (2011) A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol 18(12):1424–1427

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Durbin AP (2016) Dengue antibody and Zika: friend or foe? Trends Immunol 37(10):635–636

    Article  CAS  PubMed  Google Scholar 

  30. Eigenbrot C, Randal M, Presta L, Carter P, Kossiakoff AA (1993) X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol 229(4):969–995

    Article  CAS  PubMed  Google Scholar 

  31. Falzarano D, Geisbert TW, Feldmann H (2011) Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines 10(1):63–77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Feldmann H, Geisbert TW (2011) Ebola haemorrhagic fever. Lancet 377(9768):849–862

    Article  PubMed  PubMed Central  Google Scholar 

  33. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, Hensley LE, Geisbert TW (2007) Effective post-exposure treatment of Ebola infection. PLoS Pathog 3(1):e2

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Fellouse FA, Esaki K, Birtalan S, Raptis D, Cancasci VJ, Koide A, Jhurani P, Vasser M, Wiesmann C, Kossiakoff AA, Koide S, Sidhu SS (2007) High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol 373(4):924–940

    Article  CAS  PubMed  Google Scholar 

  35. Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS (2005) Molecular recognition by a binary code. J Mol Biol 348(5):1153–1162

    Article  CAS  PubMed  Google Scholar 

  36. Fellouse FA, Wiesmann C, Sidhu SS (2004) Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A 101(34):12467–12472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Fleishman SJ, Whitehead TA, Ekiert DC, Dreyfus C, Corn JE, Strauch EM, Wilson IA, Baker D (2011) Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332(6031):816–821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Fu Y, Zhang Z, Sheehan J, Avnir Y, Ridenour C, Sachnik T, Sun J, Hossain MJ, Chen LM, Zhu Q, Donis RO, Marasco WA (2016) A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve. Nat Commun 7:12780

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C (2006) Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 281(10):6625–6631

    Article  CAS  PubMed  Google Scholar 

  40. Gamblin SJ, Skehel JJ (2010) Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285(37):28403–28409

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Gao J, Sidhu SS, Wells JA (2009) Two-state selection of conformation-specific antibodies. Proc Natl Acad Sci U S A 106(9):3071–3076

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Garrard LJ, Yang M, O’Connell MP, Kelley RF, Henner DJ (1991) Fab assembly and enrichment in a monovalent phage display system. Biotechnology (N Y) 9(12):1373–1377

    Article  CAS  Google Scholar 

  43. Geisbert TW, Bausch DG, Feldmann H (2010) Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20(6):344–357

    Article  PubMed  PubMed Central  Google Scholar 

  44. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, Paragas J, Matthias L, Smith MA, Jones SM, Hensley LE, Feldmann H, Jahrling PB (2008) Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 4(11):e1000225

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM (2008) Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 82(11):5664–5668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I (2006) Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193(12):1650–1657

    Article  CAS  PubMed  Google Scholar 

  47. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I (2010) Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375(9729):1896–1905

    Article  CAS  PubMed  Google Scholar 

  48. Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR (2014) The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol 32(2):158–168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Geyer CR, McCafferty J, Dubel S, Bradbury AR, Sidhu SS (2012) Recombinant antibodies and in vitro selection technologies. Methods Mol Biol 901:11–32

    Article  CAS  PubMed  Google Scholar 

  50. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 109(16):6205–6210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, Ni I, Mei L, Sundar PD, Day GM, Cox D, Rajpal A, Pons J (2009) Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci U S A 106(48):20216–20221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Gong R, Wang Y, Ying T, Dimitrov DS (2012) Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn. PLoS One 7(8):e42288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68(3):295–303

    Article  PubMed  Google Scholar 

  54. Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P (2011) Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 204(1):103–114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Graham BS, Ambrosino DM (2015) History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS 10(3):129–134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ et al (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13(14):3245–3260

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Gunn BM, Alter G (2016) Modulating antibody functionality in infectious disease and vaccination. Trends Mol Med 22(11):969–982

    Article  CAS  PubMed  Google Scholar 

  58. Gustchina E, Li M, Ghirlando R, Schuck P, Louis JM, Pierson J, Rao P, Subramaniam S, Gustchina A, Clore GM, Wlodawer A (2013) Complexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41. PLoS One 8(11):e78187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Gustchina E, Li M, Louis JM, Anderson DE, Lloyd J, Frisch C, Bewley CA, Gustchina A, Wlodawer A, Clore GM (2010) Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog 6(11):e1001182

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Gustchina E, Louis JM, Frisch C, Ylera F, Lechner A, Bewley CA, Clore GM (2009) Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology 393(1):112–119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Gustchina E, Louis JM, Lam SN, Bewley CA, Clore GM (2007) A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol 81(23):12946–12953

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Harris LJ, Larson SB, Hasel KW, McPherson A (1997) Refined structure of an intact IgG2a monoclonal antibody. Biochemistry 36(7):1581–1597

    Article  CAS  PubMed  Google Scholar 

  63. Harrison JS, Higgins CD, Chandran K, Lai JR (2011) Designed protein mimics of the Ebola virus glycoprotein GP2 alpha-helical bundle: stability and pH effects. Protein Sci 20(9):1587–1596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Hey A (2015) History and practice: antibodies in infectious diseases. Microbiol Spectr 3(2):AID-0026-2014

    Google Scholar 

  65. Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, Rem L, Frans N, Daukandt M, Pieters H, van Hegelsom R, Neer NC, Nastri HG, Rondon IJ, Leeds JA, Hufton SE, Huang L, Kashin I, Devlin M, Kuang G, Steukers M, Viswanathan M, Nixon AE, Sexton DJ, Hoogenboom HR, Ladner RC (2005) Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 23(3):344–348

    Article  CAS  PubMed  Google Scholar 

  66. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G (1991) Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19(15):4133–4137

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Hoogenboom HR, Winter G (1992) By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 227(2):381–388

    Article  CAS  PubMed  Google Scholar 

  68. Hornsby M, Paduch M, Miersch S, Saaf A, Matsuguchi T, Lee B, Wypisniak K, Doak A, King D, Usatyuk S, Perry K, Lu V, Thomas W, Luke J, Goodman J, Hoey RJ, Lai D, Griffin C, Li Z, Vizeacoumar FJ, Dong D, Campbell E, Anderson S, Zhong N, Graslund S, Koide S, Moffat J, Sidhu S, Kossiakoff A, Wells J (2015) A high through-put platform for recombinant antibodies to folded proteins. Mol Cell Proteomics 14(10):2833–2847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Hou D, Chen C, Seely EJ, Chen S, Song Y (2016) High-throughput sequencing-based immune repertoire study during infectious disease. Front Immunol 7:336

    Article  PubMed  PubMed Central  Google Scholar 

  70. Huang JX, Bishop-Hurley SL, Cooper MA (2012) Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother 56(9):4569–4582

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Kang AS, Jones TM, Burton DR (1991) Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc Natl Acad Sci U S A 88(24):11120–11123

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Karauzum H, Chen G, Abaandou L, Mahmoudieh M, Boroun AR, Shulenin S, Devi VS, Stavale E, Warfield KL, Zeitlin L, Roy CJ, Sidhu SS, Aman MJ (2012) Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome. J Biol Chem 287(30):25203–25215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M, Horowitz M, Horowitz L, Palese P, Bhatt RR, Lerner RA (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 105(16):5986–5991

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Kim DY, Hussack G, Kandalaft H, Tanha J (2014) Mutational approaches to improve the biophysical properties of human single-domain antibodies. Biochim Biophys Acta 1844(11):1983–2001

    Article  CAS  PubMed  Google Scholar 

  75. Kishida S (2007) Progressive multifocal leukoencephalopathy – epidemiology, clinical pictures, diagnosis and therapy. Brain Nerve 59(2):125–137

    CAS  Google Scholar 

  76. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle J, Pluckthun A, Virnekas B (2000) Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 296(1):57–86

    Article  CAS  PubMed  Google Scholar 

  77. Knowles WA (2006) Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 577:19–45

    Article  CAS  PubMed  Google Scholar 

  78. Koday MT, Nelson J, Chevalier A, Koday M, Kalinoski H, Stewart L, Carter L, Nieusma T, Lee PS, Ward AB, Wilson IA, Dagley A, Smee DF, Baker D, Fuller DH (2016) A computationally designed Hemagglutinin stem-binding protein provides in vivo protection from influenza independent of a host immune response. PLoS Pathog 12(2):e1005409

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Koellhoffer JF, Chen G, Sandesara RG, Bale S, Saphire EO, Chandran K, Sidhu SS, Lai JR (2012) Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein. Chembiochem 13(17):2549–2557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Koerber JT, Thomsen ND, Hannigan BT, Degrado WF, Wells JA (2013) Nature-inspired design of motif-specific antibody scaffolds. Nat Biotechnol 31(10):916–921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Koide A, Gilbreth RN, Esaki K, Tereshko V, Koide S (2007) High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci U S A 104(16):6632–6637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Koide S, Sidhu SS (2009) The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins. ACS Chem Biol 4(5):325–334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K, Ozorowski G, Soto C, Taft JD, Bailer RT, Cale EM, Chen L, Choi CW, Chuang GY, Doria-Rose NA, Druz A, Georgiev IS, Gorman J, Huang J, Joyce MG, Louder MK, Ma X, McKee K, O’Dell S, Pancera M, Yang Y, Blanchard SC, Mothes W, Burton DR, Koff WC, Connors M, Ward AB, Kwong PD, Mascola JR (2016) Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352(6287):828–833

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL (1999) JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52(2):253–260

    Article  CAS  PubMed  Google Scholar 

  85. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155(12):2083–2103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Kuhn P, Fuhner V, Unkauf T, Moreira GM, Frenzel A, Miethe S, Hust M (2016) Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. Proteomics Clin Appl 10(9–10):922–948

    Article  CAS  PubMed  Google Scholar 

  87. Kuruganti S, Miersch S, Deshpande A, Speir JA, Harris BD, Schriewer JM, Buller RM, Sidhu SS, Walter MR (2016) Cytokine activation by antibody fragments targeted to cytokine-receptor signaling complexes. J Biol Chem 291(1):447–461

    Article  CAS  PubMed  Google Scholar 

  88. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393(6686):648–659

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Larkin EA, Stiles BG, Ulrich RG (2010) Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One 5(10):e13253

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G (2004) High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340(5):1073–1093

    Article  CAS  PubMed  Google Scholar 

  91. Lee CV, Sidhu SS, Fuh G (2004) Bivalent antibody phage display mimics natural immunoglobulin. J Immunol Methods 284(1–2):119–132

    Article  CAS  PubMed  Google Scholar 

  92. Lee J, Boutz DR, Chromikova V, Joyce MG, Vollmers C, Leung K, Horton AP, DeKosky BJ, Lee CH, Lavinder JJ, Murrin EM, Chrysostomou C, Hoi KH, Tsybovsky Y, Thomas PV, Druz A, Zhang B, Zhang Y, Wang L, Kong WP, Park D, Popova LI, Dekker CL, Davis MM, Carter CE, Ross TM, Ellington AD, Wilson PC, Marcotte EM, Mascola JR, Ippolito GC, Krammer F, Quake SR, Kwong PD, Georgiou G (2016) Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med 22(12):1456–1464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454(7201):177–182

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Lee JE, Saphire EO (2009) Ebolavirus glycoprotein structure and mechanism of entry. Futur Virol 4(6):621–635

    Article  CAS  Google Scholar 

  95. Lee JE, Saphire EO (2009) Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol 19(4):408–417

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, Kim J, Park S, Darwish M, Lee BC, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S (2015) Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 527(7578):323–328

    Article  CAS  PubMed  Google Scholar 

  97. Lerner RA (2011) Rare antibodies from combinatorial libraries suggests an S.O.S. component of the human immunological repertoire. Mol BioSyst 7(4):1004–1012

    Article  CAS  PubMed  Google Scholar 

  98. Lerner RA (2016) Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol 16(8):498–508

    Article  CAS  PubMed  Google Scholar 

  99. Lim BN, Tye GJ, Choong YS, Ong EB, Ismail A, Lim TS (2014) Principles and application of antibody libraries for infectious diseases. Biotechnol Lett 36(12):2381–2392

    Article  CAS  PubMed  Google Scholar 

  100. Liu CC, Mack AV, Tsao ML, Mills JH, Lee HS, Choe H, Farzan M, Schultz PG, Smider VV (2008) Protein evolution with an expanded genetic code. Proc Natl Acad Sci U S A 105(46):17688–17693

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Liu Y, Regula LK, Stewart A, Lai JR (2011) Synthetic Fab fragments that bind the HIV-1 gp41 heptad repeat regions. Biochem Biophys Res Commun 413(4):611–615

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23(9):1117–1125

    Article  CAS  PubMed  Google Scholar 

  103. Luz D, Chen G, Maranhao AQ, Rocha LB, Sidhu S, Piazza RM (2015) Development and characterization of recombinant antibody fragments that recognize and neutralize in vitro Stx2 toxin from Shiga toxin-producing Escherichia coli. PLoS One 10(3):e0120481

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Mahon CM, Lambert MA, Glanville J, Wade JM, Fennell BJ, Krebs MR, Armellino D, Yang S, Liu X, O’Sullivan CM, Autin B, Oficjalska K, Bloom L, Paulsen J, Gill D, Damelin M, Cunningham O, Finlay WJ (2013) Comprehensive interrogation of a minimalist synthetic CDR-H3 library and its ability to generate antibodies with therapeutic potential. J Mol Biol 425(10):1712–1730

    Article  CAS  PubMed  Google Scholar 

  105. Malashkevich VN, Schneider BJ, McNally ML, Milhollen MA, Pang JX, Kim PS (1999) Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci U S A 96(6):2662–2667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348(6301):552–554

    Article  CAS  PubMed  Google Scholar 

  107. Miersch S, Sidhu SS (2012) Synthetic antibodies: concepts, potential and practical considerations. Methods 57(4):486–498

    Article  CAS  PubMed  Google Scholar 

  108. Miller EH, Chandran K (2012) Filovirus entry into cells – new insights. Curr Opin Virol 2(2):206–214

    Article  CAS  PubMed  Google Scholar 

  109. Moekotte AL, Huson MA, van der Ende AJ, Agnandji ST, Huizenga E, Goorhuis A, Grobusch MP (2016) Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opin Investig Drugs:1–11

    Google Scholar 

  110. Morrison C (2015) Antibacterial antibodies gain traction. Nat Rev Drug Discov 14(11):737–738

    Article  CAS  PubMed  Google Scholar 

  111. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO (2014) Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 111(48):17182–17187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Na H, Laver JD, Jeon J, Singh F, Ancevicius K, Fan Y, Cao WX, Nie K, Yang Z, Luo H, Wang M, Rissland O, Westwood JT, Kim PM, Smibert CA, Lipshitz HD, Sidhu SS (2016) A high-throughput pipeline for the production of synthetic antibodies for analysis of ribonucleoprotein complexes. RNA 22(4):636–655

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Nelson AL (2010) Antibody fragments: hope and hype. MAbs 2(1):77–83

    Article  PubMed  PubMed Central  Google Scholar 

  114. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767–774

    Article  CAS  PubMed  Google Scholar 

  115. Neu U, Maginnis MS, Palma AS, Stroh LJ, Nelson CD, Feizi T, Atwood WJ, Stehle T (2010) Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8(4):309–319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Neu U, Stehle T, Atwood WJ (2009) The Polyomaviridae: contributions of virus structure to our understanding of virus receptors and infectious entry. Virology 384(2):389–399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Newton K, Matsumoto ML, Wertz IE, Kirkpatrick DS, Lill JR, Tan J, Dugger D, Gordon N, Sidhu SS, Fellouse FA, Komuves L, French DM, Ferrando RE, Lam C, Compaan D, Yu C, Bosanac I, Hymowitz SG, Kelley RF, Dixit VM (2008) Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134(4):668–678

    Article  CAS  PubMed  Google Scholar 

  118. Nilvebrant J, Tessier PM, Sidhu SS (2016) Engineered autonomous human variable domains. Curr Pharm Des 22(43):6527–6537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD (2010) Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A 107(3):1166–1171

    Article  CAS  PubMed  Google Scholar 

  120. Pappas L, Foglierini M, Piccoli L, Kallewaard NL, Turrini F, Silacci C, Fernandez-Rodriguez B, Agatic G, Giacchetto-Sasselli I, Pellicciotta G, Sallusto F, Zhu Q, Vicenzi E, Corti D, Lanzavecchia A (2014)Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516(7531):418–422

    Article  CAS  PubMed  Google Scholar 

  121. Persson H, Lantto J, Ohlin M (2006) A focused antibody library for improved hapten recognition. J Mol Biol 357(2):607–620

    Article  CAS  PubMed  Google Scholar 

  122. Persson H, Ye W, Wernimont A, Adams JJ, Koide A, Koide S, Lam R, Sidhu SS (2013) CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol 425(4):803–811

    Article  CAS  PubMed  Google Scholar 

  123. Pietropaolo V, Videtta M, Fioriti D, Mischitelli M, Arancio A, Orsi N, Degener AM (2003) Rearrangement patterns of JC virus noncoding control region from different biological samples. J Neurovirol 9(6):603–611

    Article  CAS  PubMed  Google Scholar 

  124. Prassler J, Thiel S, Pracht C, Polzer A, Peters S, Bauer M, Norenberg S, Stark Y, Kolln J, Popp A, Urlinger S, Enzelberger M (2011) HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol 413(1):261–278

    Article  CAS  PubMed  Google Scholar 

  125. Qiu X, Audet J, Lv M, He S, Wong G, Wei H, Luo L, Fernando L, Kroeker A, Fausther Bovendo H, Bello A, Li F, Ye P, Jacobs M, Ippolito G, Saphire EO, Bi S, Shen B, Gao GF, Zeitlin L, Feng J, Zhang B, Kobinger GP (2016) Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med 8(329):329ra333

    Article  Google Scholar 

  126. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520):47–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Reichert JM (2016) Antibodies to watch in 2017. MAbs 9(2):167–181

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  128. Rizk SS, Paduch M, Heithaus JH, Duguid EM, Sandstrom A, Kossiakoff AA (2011) Allosteric control of ligand-binding affinity using engineered conformation-specific effector proteins. Nat Struct Mol Biol 18(4):437–442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Rudick RA, O’Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, Goelz SE (2010) Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68(3):304–310

    Article  PubMed  Google Scholar 

  130. Safdari Y, Farajnia S, Asgharzadeh M, Khalili M (2013) Antibody humanization methods – a review and update. Biotechnol Genet Eng Rev 29:175–186

    Article  CAS  PubMed  Google Scholar 

  131. Sanchez A, Trappier SG, Mahy BW, Peters CJ, Nichol ST (1996) The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 93(8):3602–3607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Saphire EO (2013) An update on the use of antibodies against the filoviruses. Immunotherapy 5(11):1221–1233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Saylor C, Dadachova E, Casadevall A (2009) Monoclonal antibody-based therapies for microbial diseases. Vaccine 27(Suppl 6):G38–G46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Schoonbroodt S, Steukers M, Viswanathan M, Frans N, Timmermans M, Wehnert A, Nguyen M, Ladner RC, Hoet RM (2008) Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates. J Immunol 181(9):6213–6221

    Article  CAS  PubMed  Google Scholar 

  135. Sheehan J, Marasco WA (2015) Phage and yeast display. Microbiol Spectr 3(1):AID-0028-2014

    Article  PubMed  CAS  Google Scholar 

  136. Sidhu SS, Fellouse FA (2006) Synthetic therapeutic antibodies. Nat Chem Biol 2(12):682–688

    Article  CAS  PubMed  Google Scholar 

  137. Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G (2004) Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol 338(2):299–310

    Article  CAS  PubMed  Google Scholar 

  138. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69:531–569

    Article  CAS  PubMed  Google Scholar 

  139. Soderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Aberg AM, Nilsson A, Jansson B, Ohlin M, Wingren C, Danielsson L, Carlsson R, Borrebaeck CA (2000) Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 18(8):852–856

    Article  CAS  PubMed  Google Scholar 

  140. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza a viruses. Nat Struct Mol Biol 16(3):265–273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Sunyaev SR, Lugovskoy A, Simon K, Gorelik L (2009) Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 5(2):e1000368

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  142. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3(12):e3942

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  143. Tiller T (2011) Single B cell antibody technologies. New Biotechnol 28(5):453–457

    Article  CAS  Google Scholar 

  144. Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, Hessling M, Daubert D, Felderer K, Kaden S, Kolln J, Enzelberger M, Urlinger S (2013) A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs 5(3):445–470

    Article  PubMed  PubMed Central  Google Scholar 

  145. Tung CP, Chen IC, Yu CM, Peng HP, Jian JW, Ma SH, Lee YC, Jan JT, Yang AS (2015) Discovering neutralizing antibodies targeting the stem epitope of H1N1 influenza hemagglutinin with synthetic phage-displayed antibody libraries. Sci Rep 5:15053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Tyler KL (2010) Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 68(3):271–274

    Article  PubMed  Google Scholar 

  147. Unkauf T, Miethe S, Fuhner V, Schirrmann T, Frenzel A, Hust M (2016) Generation of recombinant antibodies against toxins and viruses by phage display for diagnostics and therapy. Adv Exp Med Biol 917:55–76

    Article  CAS  PubMed  Google Scholar 

  148. Wang B, Kluwe CA, Lungu OI, DeKosky BJ, Kerr SA, Johnson EL, Jung J, Rezigh AB, Carroll SM, Reyes AN, Bentz JR, Villanueva I, Altman AL, Davey RA, Ellington AD, Georgiou G (2015) Facile discovery of a diverse panel of anti-Ebola virus antibodies by immune repertoire mining. Sci Rep 5:13926

    Article  PubMed  PubMed Central  Google Scholar 

  149. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402–405

    Article  CAS  PubMed  Google Scholar 

  150. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE Jr, Aman MJ, Dye JM, Lai JR, Chandran K (2016) A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science 354(6310):350–354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Weis WI, Brunger AT, Skehel JJ, Wiley DC (1990) Refinement of the influenza virus hemagglutinin by simulated annealing. J Mol Biol 212(4):737–761

    Article  CAS  PubMed  Google Scholar 

  152. Weissenhorn W, Carfi A, Lee KH, Skehel JJ, Wiley DC (1998) Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 2(5):605–616

    Article  CAS  PubMed  Google Scholar 

  153. Whitehead TA, Chevalier A, Song Y, Dreyfus C, Fleishman SJ, De Mattos C, Myers CA, Kamisetty H, Blair P, Wilson IA, Baker D (2012) Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol 30(6):543–548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Wong G, Qiu X, Olinger GG, Kobinger GP (2014) Post-exposure therapy of filovirus infections. Trends Microbiol 22(8):456–463

    Article  CAS  PubMed  Google Scholar 

  155. Wong SCM (2013) The generation of synthetic antibody reagents for Clostridium difficile toxins. Master, University of Toronto

    Google Scholar 

  156. Wyrzucki A, Dreyfus C, Kohler I, Steck M, Wilson IA, Hangartner L (2014) Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody. J Virol 88(12):7083–7092

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  157. Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS (2009) A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 387(2):387–392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Xie J, Yea K, Zhang H, Moldt B, He L, Zhu J, Lerner RA (2014) Prevention of cell death by antibodies selected from intracellular combinatorial libraries. Chem Biol 21(2):274–283

    Article  CAS  PubMed  Google Scholar 

  159. Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF 3rd (1995) CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254(3):392–403

    Article  CAS  PubMed  Google Scholar 

  160. Ying T, Gong R, Ju TW, Prabakaran P, Dimitrov DS (2014) Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta 1844(11):1977–1982

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Ying T, Wang Y, Feng Y, Prabakaran P, Gong R, Wang L, Crowder K, Dimitrov DS (2015) Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. MAbs 7(5):922–930

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Zahnd C, Spinelli S, Luginbuhl B, Amstutz P, Cambillau C, Pluckthun A (2004) Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem 279(18):18870–18877

    Article  CAS  PubMed  Google Scholar 

  163. Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R, Dimitrov DS (2013) Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Virol Sin 28(2):71–80

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, University of Toronto, Toronto, ON, Canada

    Gang Chen, Sachdev S. Sidhu & Johan Nilvebrant

  2. Division of Protein Technology, School of Biotechnology, Royal Institute of Technology, AlbaNova University Center, Stockholm, Sweden

    Johan Nilvebrant

Authors
  1. Gang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sachdev S. Sidhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johan Nilvebrant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johan Nilvebrant .

Editor information

Editors and Affiliations

  1. Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang, Malaysia

    Theam Soon Lim

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chen, G., Sidhu, S.S., Nilvebrant, J. (2017). Synthetic Antibodies in Infectious Disease. In: Lim, T. (eds) Recombinant Antibodies for Infectious Diseases. Advances in Experimental Medicine and Biology, vol 1053. Springer, Cham. https://doi.org/10.1007/978-3-319-72077-7_5

Download citation

Publish with us

Policies and ethics

Search

Navigation